Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Testosterone Gel Makers Brace For REMS, Black Box Warning

This article was originally published in The Pink Sheet Daily

Executive Summary

Risks of skin contact with children and women were known, but severity of adverse events took the field by surprise.

You may also be interested in...



Beyond Individual Patients: FDA Emphasizes Public Health Role In Certain Benefit-Risk Decisions

US FDA’s new draft guidance on benefit-risk assessments for new drugs highlights cases where it can take into account broader public health implications than just the pros and cons calculus for the patients described in a drug's label. While not a new policy perse, it is one the agency seems to have only grudgingly employed in the past.

Endo's Fortesta To Join Crowded Testosterone Treatment Market In Q1

FDA approved the testosterone gel despite concerns about secondary exposure, but Fortesta will be competing against entrenched rivals and a new treatment from Eli Lilly.

Endo's Fortesta To Join Crowded Testosterone Treatment Market In Q1

FDA approved the testosterone gel despite concerns about secondary exposure, but Fortesta will be competing against entrenched rivals and a new treatment from Eli Lilly.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel